Find Clinical Trial

A phase 1, open label, non-comparative, monocenter study to evaluate the safety and the ability of UCART19 to induce molecular remission in paediatric patients with relapsed /refractory B acute lymphoblastic leukaemia – UCART19_PALL

← Back
Study Phase

Phase 1

Therapeutic Area


IndicationBlood cancer
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device


Active Substance CodeS068587
Protocol CodeCL1-68587-001
EudraCT Code2015-004293-15
NCT CodeNCT02808442

Documents and links

Lay summary
Results summary READ MORE
Scientific publication READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.

More information

UCART-19  is anti-CD-19 allogenic CAR-T product developed based on exclusive license granted by Cellectis to Servier. UCART-19 uses Cellectis’ technologies, including TALEN® gene-editing technologies

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.